Renald Meçani

Renald Meçani

Auto-generated profile, based on publicly available information

Renald Meçani

Division of Endocrinology and Diabetology, Department of Internal Medicine Medical University of Graz Graz Austria

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2025 in Aesthetic Plastic Surgery
Verified
Journal Article
Open access
PDF file
RMRenald Meçani
Renald Meçani
MAMojgan Amiri
Mojgan Amiri
JKJonathan Kadouch
Jonathan Kadouch
DSDusan Sajic
Dusan Sajic
FLFrank Lin
Frank Lin
Taulant MukaTaulant Muka
Taulant Muka
Background: The use of dermal fillers has become increasingly popular in aesthetic medicine for facial rejuvenation and skin enhancement. Hyaluronic acid (HA) and calcium hydroxylapatite (CaHA) are particularly well-known for their unique benefits. This systematic review evaluates the combinations (e.g., using two separate treatments together) and hybrid treatments of HA and CaHA (e.g., direct syringe-to-syringe mixing), focusing on their mechanisms of action, aesthetic effectiveness, patient satisfaction, and safety. Methods: Six bibliographic databases were searched for human and non-human studies that explored the mechanistic effects of combined and hybrid HA and CaHA treatments, and their aesthetic effectiveness, skin quality, satisfaction, and safety were included. Due to high heterogeneity among included studies, a qualitative synthesis of the evidence was performed. Results: The combination of HA and CaHA stimulates collagen synthesis through different molecular pathways. The combined and hybrid treatments are associated with high aesthetic effectiveness in various facial areas, as reported by both investigators and subjects. Additionally, the combinations and hybrid treatments show high satisfaction rates and have a safe profile, with minor, self-resolving adverse effects. A trend of slight decline in both aesthetic improvement and treatment satisfaction was observed after six months. Conclusions: The combinations and hybrid treatments of HA and CaHA appear to be a promising, safe, and efficacious treatment for facial rejuvenation, offering both immediate volumizing effects and longer-term benefits through collagen synthesis. Future research should employ rigorous study designs aimed at refining treatment protocols and generating strong, long-term evidence for the safety and effectiveness of this combination or hybrid therapy in aesthetic medicine. Level of Evidence II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

4 November 2024 in Diabetologia
Verified
Journal Article
Open access
PDF file
GGGillian L. Garden
Gillian L. Garden
KFKa Siu Fan
Ka Siu Fan
MPMegan Paterson
Megan Paterson
FSFariba Shojaee-Moradie
Fariba Shojaee-Moradie
MIMonique Borg Inguanez
Monique Borg Inguanez
TPthomas pieber
thomas pieber
Aims/hypothesis: Glycaemic control and clinical outcomes in diabetes are improved by continuous subcutaneous insulin infusion (CSII). Atmospheric pressure changes during flights may affect insulin delivery from pumps and cause unintended metabolic consequences, including hypoglycaemia, in people with type 1 diabetes. The present report evaluates both hypobaric flight simulation and real-world data in pilots using insulin pumps while flying. Methods: In the flight simulation part of this study, an in vitro study of insulin pumps was conducted in a hypobaric chamber, de-pressurised to 550 mmHg to mimic the atmospheric pressure changes in airliner cabins during commercial flights. Insulin delivery rates and bubble formation were recorded for standard flight protocol. Insulin infusion sets, without pumps, were tested in a simulated rapid decompression scenario. The real-world observational study was a 7.5-year retrospective cohort study in which pre- and in-flight self-monitored blood glucose (SMBG) values were monitored in pilots with insulin-treated diabetes. Commercial and private pilots granted a medical certificate to fly within the European Union Aviation Safety Agency approved protocol and receiving insulin either by pump or multiple daily injections (MDI) were included. Results: In the flight simulation study, full cartridges over-delivered 0.60 U of insulin during a 20 min ascent and under-delivered by 0.51 U during descent compared with ground-level performance. During emergency rapid decompression, 5.6 U of excess insulin was delivered. In the real-world study, seven pilots using CSII recorded 4656 SMBG values during 2345 h of flying across 1081 flights. Only 33 (0.7%) values were outside an acceptable safe range (5.0–15.0 mmol/l [90–270 mg/dl]). No clinically significant fall in the median SMBG concentration was observed after aircraft ascent and no in-flight SMBG values were within the hypoglycaemic range (<4.0 mmol/l [<72 mg/dl]). Compared with pilots receiving MDI therapy, pilots using CSII recorded more SMBG values within the acceptable range (99.3% vs 97.5%), fewer values in the low red range (0.02% vs 0.1%), fewer in-flight out-of-range values (0.2% vs 1.3%) and maintained stricter glycaemic control during flight. Conclusions/interpretation: Ambient pressure reduction during simulated flights results in bubble formation and expansion within insulin cartridges. This causes unintended delivery of small insulin doses independent of pre-determined delivery rates and represents the maximum amount of insulin that could be delivered and retracted. However, in vivo, pilots using CSII in-flight did not experience a fall in blood glucose or episodes of hypoglycaemia during these atmospheric pressure changes and the use of insulin pumps can be endorsed in view of their clinical benefits. Graphical

2 January 2026 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
RMRenald Meçani
Renald Meçani
SBSilvia Basta
Silvia Basta
PBPetra M. Baumann
Petra M. Baumann
MCMonika Cigler
Monika Cigler
OHOmaima El Hakouni
Omaima El Hakouni
Julia MaderJulia Mader
Julia Mader
Aims: Continuous glucose monitoring (CGM) systems are increasingly used, but their accuracy under flight‐conditions remains insufficiently studied. We assessed sensor accuracy of four CGMs during in‐flight (mid‐haul) and ground conditions. Materials and Methods: Participants ( n = 20) wore four sensors (Abbott Libre 3, Dexcom G7, Medtronic Simplera, and Sinocare iCan i3) in parallel, inserted 1 day prior to experiment. Capillary reference measurements were performed every 30 min. Accuracy evaluation included: proportion of CGM values within 10% of comparator glucose levels >100 mg/dL or within 10 mg/days of comparator levels ≤100 mg/dL (%10/10), along with %20/20 agreement rates, mean absolute relative difference (MARD), Consensus error grid. Results: Twenty participants with type 1 diabetes (age: 37.9 ± 12.8 years, HbA1c: 52.3 ± 4.9 mmol/mol, diabetes duration 19.25 ± 10.6 years) were included in the analysis. Data from 297 sensors with 3473 matched pairs (G7/Libre3/Simplera/i3) were analysed. The overall MARDs were: 9.5% ± 3.3% (G7), 9.6% ± 3.8% (Libre3), 19.9% ± 6.2% (Simplera) and 15.7% ± 6.6% (i3). Overall %20/20 and %10/10 agreement rates were 90.6%/70.2% (G7), 90.8%/66.8% (Libre3), 63.6%/37.8% (Simplera) and 72.5%/42.2% (i3) respectively. The proportion of values in Zones A and B of the Consensus error grid was 98.9% (G7), 99.0% (Libre 3), 94.5% (Simplera) and 97.5% (i3). Prandial state and flight phase had limited influence on the relative performance ranking of the devices. Conclusions: G7 and Libre3 showed consistently higher accuracy and clinical reliability across various phases of flight and ground conditions. Simplera and i3 exhibited greater variability in accuracy. These findings suggest that while modern CGMs could support diabetes management in aviation, individual system performance may differ under specific operational conditions.

29 March 2026 in Diabetic Medicine
Verified
Journal Article
Open access
MCMonika Cigler
Monika Cigler
OEOmaima El‐Hakouni
Omaima El‐Hakouni
RMRenald Mecani
Renald Mecani
FPFrançois Pouwer
François Pouwer
EAEvertine J. Abbink
Evertine J. Abbink
Julia MaderJulia Mader
Julia Mader
Background and Aims: In people with insulin‐treated diabetes experiencing hypoglycaemia, the multicentre Hypo‐METRICS study found that 60% of sensor‐detected hypoglycaemic episodes (SDH) were asymptomatic, and over 40% of person‐reported hypoglycaemia (PRH) occurred at glucose levels ≥70 mg/dL (3.9 mmol/L). This subanalysis explored participants' experiences of these episodes to identify possible clinical implications. Methods: Fifty‐eight Austrian participants received a 15‐item questionnaire on their experience of asymptomatic hypoglycaemia and symptoms at glucose levels ≥70 mg/dL (3.9 mmol/L). Results: The response rate was 86% ( n = 50). Among all participants, 56% ( n = 28) reported experiencing hypoglycaemic symptoms at glucose levels ≥70 mg/dL (3.9 mmol/L) “sometimes” or “often.” They attributed this to a combination of a threshold shift due to chronic hyperglycaemia, rapid glucose decline and fear of hypoglycaemia. 68% of all SDH < 70 mg/dL and 59% of those below the clinically critical level of 54 mg/dL were asymptomatic. Conclusion: These results demonstrate that SDH and PRH each capture different, yet equally important, dimensions of the hypoglycaemia experience. Relying on only one source of information inevitably provides an incomplete picture. By integrating the patient's voice, diabetes professionals can provide appropriate support and tailor continuous glucose monitoring (CGM) alarm settings and treatment plans to truly meet individual needs.

23 January 2026 in Diabetic Medicine
Verified
Journal Article
Open access
RMRenald Meçani
Renald Meçani
TMTaulant Muka
Taulant Muka
MCMonika Cigler
Monika Cigler
SBSilvia Basta
Silvia Basta
OEOmaima El‐Hakouni
Omaima El‐Hakouni
Julia MaderJulia Mader
Julia Mader
Background: Despite advancements in diabetes management technologies, restrictions on insulin‐treated pilots persist, underscoring the need to evaluate the safety, efficacy and performance of these technologies in aviation settings. This systematic review aims to summarize the available evidence on the performance, safety and effectiveness of diabetes technologies in aviation settings. Materials: Four bibliographic databases were searched, and eligible studies assessing diabetes technologies in‐flight or simulated aviation conditions, focusing on glycaemic control and safety, were included. Due to high heterogeneity among the included studies, a qualitative synthesis of the evidence was performed. This systematic review was registered with PROSPERO (CRD42025634909). Results: Out of 522 references, six human and in‐vitro studies were included for final analysis. Human studies demonstrated the high accuracy of continuous glucose monitors (CGM) and good glycaemic control with insulin pump therapy. Automated insulin delivery (AID) systems demonstrated effective glycaemic control and safety under hypobaric conditions. However, hypoglycaemia during extended fasting was noted. In‐vitro studies highlighted risks, such as excess insulin delivery during ascent and reduced delivery during descent, influenced by pressure changes. CGMs exhibited minor signal variability in hypobaric conditions. Conclusion: Diabetes technologies, particularly CGMs and AID systems, show promise in aviation environments. However, challenges such as insulin delivery variability, hypoglycaemia during fasting and the limited generalizability of hypobaric studies to real‐flight conditions warrant further investigation. Future research should focus on larger, more diverse cohorts, real‐world data, standardized protocols and a broader range of devices to further define the safety of their safety for aviation‐specific diabetes management.

18 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Taulant MukaTaulant Muka
Taulant Muka
PZPetra Zimmermann
Petra Zimmermann
LFLeonora Fisniku
Leonora Fisniku
RMRenald Mecani
Renald Mecani
ILIrene Lambrinoudaki
Irene Lambrinoudaki
VBVisar Berisha
Visar Berisha
Introduction Continuing medical education (CME) is essential for more than 100 million healthcare professionals worldwide, supporting enhancement of knowledge, skills, and patient outcomes. With a growing shift towards online and blended CME formats, expert-informed AI-based training (EIAT) is a novel e-training approach enabling rapid course creation and a timely content updates. However, its effectiveness remains underexplored. Methods A within-subject pre-post study was conducted with 17 medical students and professionals . Participants first completed a self-paced EIAT module, followed by live expert-led training (LET). Knowledge acquisition was measured via pre- and post-exams for each modality. Satisfaction, engagement, learning outcomes, and content quality were assessed using a 20-item CME-relevant feedback tool aligned with European Accreditation Council for CME standards. Paired t-test and McNemar’s tests were used to compare outcomes between the two training formats. Results EIAT completion was 76%, compared to 82% for LET. Pre-test scores were lower in LET (63 ± 11.4) than EIAT (73.8 ± 11.2), though not significantly different (p = 0.14). Mean knowledge gain was 17.3 ± 13.3 for EIAT (p = 0.0005) and 29.2 ± 13.2 for LET (p = 0.003), with no significant difference between modalities (mean difference 14.2 ± 21.5, p = 0.17) or in post-test scores (93.5 ± 5.5 vs. 93.3 ± 9.3, p = 0.79). Both formats achieved high satisfaction, with mean recommendation scores of 9.7 (SD = 0.67) for EIAT and 10 (SD = 0.0) for LET, respectively, and no significant differences across most evaluation domains (p > 0.05). Engagement was strong in both groups, though 71.4% of LET participants reported being ‘enthusiastically involved’ compared to 60% in EIAT, and 85.8% of LET participants gaining substantial practical knowledge versus 50% for EIAT (p = 0.08). Both formats were rated highly in terms of fairness, content quality, and absence of commercial bias. Conclusion: This pilot study provides preliminiary evidence that expert-informed AI is an effective alternative or complement to traditional live CME format. These findings offer further research into EIAT’s role in scalable, high-quality CME for healthcare professionals, laying the groundwork for future research and broader implementation.